89bio Inc. PT receives Investment Bank Analyst Rating Update
- ByInvesting.com-
Symbol | Exchange | Currency |
|---|
Investing.com - 89bio (NASDAQ: ETNB) reported first quarter EPS of $-0.48, $0.21 better than the analyst estimate of $-0.69. Revenue for the quarter came in at $0.00 versus the...
89bio, Inc. (Nasdaq: NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver...
89Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The Company's lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). NASH is a severe form of nonalcoholic fatty liver disease (NAFLD), characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, hepatocellular carcinoma (HCC) and death. The Company is evaluating the potential opportunity for pegozafermin in these fibrosis stage F4 patients. SHTG is a condition identified by severely elevated levels of triglycerides. The Company has initiated its Phase II trial (ENTRIGUE) in SHTG patients.
| Average | 24.88 (+127.63% Upside) |
| High | 34.00 |
| Low | 17.00 |
| Price | 10.93 |
| No. of Analysts | 8 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Neutral |
| Technical Indicators | Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 197.58 | 198.00 | 188.04 | +14.33 | +7.82% | 152.86M | NASDAQ | |||
| 159.28 | 159.40 | 156.54 | +1.88 | +1.19% | 73.84M | NASDAQ | |||
| 60.32 | 60.75 | 59.88 | -0.28 | -0.46% | 13.71M | NYSE | |||
| 202.16 | 203.55 | 197.95 | +4.35 | +2.20% | 31.79M | NASDAQ | |||
| 104.92 | 105.10 | 101.22 | +3.70 | +3.66% | 42.03M | NASDAQ | |||
| 273.78 | 275.00 | 269.52 | +1.55 | +0.57% | 34.51M | NASDAQ | |||
| 40.66 | 40.91 | 40.31 | -0.15 | -0.37% | 19.97M | NYSE | |||
| 95.93 | 99.46 | 93.64 | -0.88 | -0.91% | 85.17M | NASDAQ | |||
| 100.61 | 100.85 | 98.00 | +2.90 | +2.97% | 58.46M | NASDAQ | |||
| 167.76 | 168.33 | 164.93 | +4.72 | +2.90% | 2.33M | NASDAQ | |||
| 261.99 | 263.92 | 253.81 | +2.99 | +1.15% | 54.60M | NASDAQ | |||
| 8.45 | 8.51 | 8.17 | +0.37 | +4.58% | 27.02M | NYSE | |||
| 105.84 | 105.96 | 101.86 | +3.91 | +3.84% | 33.06M | NASDAQ | |||
| 45.74 | 46.05 | 44.10 | +1.86 | +4.24% | 14.72M | NYSE | |||
| 10.28 | 10.29 | 10.28 | +0.020 | +0.19% | 223.00 | NYSE |